Lesion Progression in apoE-Deficient Mice: Implication of Chemokines and Effect of the AT1 Angiotensin II Receptor Antagonist Irbesartan
Geneviève Martin, Jean‐Marc Herbert(Sanofi (France)), Anne-Marie Marés(Inserm), Vincent Bérézowski(Genfit (France)), Paul Schaeffer(Universidad La Salle), Bart Staels(Inserm), Frédérique Dol(Sanofi (France)), Dean W. Hum(Genfit (France))
Cited by 18
Related Papers
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
|Journal of Hepatology|2014|1.5k
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
|Journal of Biological Chemistry|1999|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|943
PPAR control of metabolism and cardiovascular functions
|Nature Reviews Cardiology|2021|901